Extended Data Fig. 4: In vitro and in vivo suppression, apoptotic rate and exTreg cell formation of CARMA1-deficient Treg cells.
From: Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy

a, CD4+CD45RBhighYFP– Tconv cells and CD4+CD45RBlowYFPbright Treg cells were double-sorted to more than 98% purity from LNs and spleens of Fcre × C1+/+ × ROSA26-stopf/f-YFP mice, which allow for clear differentiation of Cre-expressing Treg cells based on high expression of soluble enhanced yellow fluorescent protein (eYFP) in addition to the YFP–Cre fusion protein. b, YFPbright Treg from Fcre × C1+/+ or Fcre/+ × C1f/+ or C1 f/f mice and CellTrace Violet-labelled Tconv cells from Fcre × C1+/+ mice were co-cultured at indicated ratios for three days in the presence of anti-CD3 antibodies and T-cell-depleted splenocytes, and suppression measured as reduction of Tconv cell proliferation. c, Treg cells of various genotypes and Tconv cells were co-adoptively transferred into Rag-deficient hosts and their respective frequency in peripheral blood was determined eight weeks later. d, CD4+YFP+ Treg cells of indicated genotypes were cultured without exogenous IL-2 on anti-CD3/CD28-coated or uncoated plates for 6 or 18 h and examined for reactivity with annexin V and the viability dye ZombieRed. e, CD4+YFPbright cells were sorted from LNs of one-year-old and Fcre/+ × C1+/+ (or C1 f/+, C1 f/f) × ROSA26-stopf/f-YFP mice and subsequently stained for expression of FOXP3 protein to determine the frequency of FOXP3– exTreg cells. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (two-way ANOVA with Sidak post hoc test in b, c; two-tailed Student’s t-test in d).